Lead with the engine. In its annual report for fiscal 2021, filed February 9, 2022, Vertex Pharmaceuticals reports full-year revenue of about $7.57 billion, and the 10-K is explicit about what drives it: the strong performance of Trikafta in the U.S., including the expanded indication of Trikafta for children with cystic fibrosis aged 6 through 11.
This is the defining shape of Vertex as the filing presents it — a company whose economics rest on a dominant cystic fibrosis franchise. The expansion to younger patients is the kind of label growth that extends a franchise’s reach without requiring a new drug, and the 10-K frames it as a contributor to the year’s performance.
The fundamentals-first read carries a built-in caution: concentration. A single therapeutic area carrying the top line is enormously profitable while it lasts, but it ties the company’s fortunes to one franchise’s durability. That is why Vertex’s filings consistently pair the CF success story with its pipeline-diversification efforts — the cash from CF is meant to fund bets beyond it.
Read forward from early 2022, the question the 10-K leaves open is whether the company can convert this CF-funded base into a second pillar before the first matures. As of this filing, the base is real and the diversification is a plan — the document records the engine, not where it eventually takes the company.
Every figure above is drawn from the company's primary SEC filing — surfaced through EdgarBeast, the SEC filing data API and evidence index — and verifiable against the filing on sec.gov.